TurnerTrends Stock Rating Report for CEGE
Data valid for week beginning July 21, 2008
|
CEGE [News]
|
Cell Genesys Inc
|
Company Profile
"Cell Genesys, Inc., a biotechnology company, engages in the development and commercialization of biological therapies for patients with cancer. It develops cell-based cancer immunotherapies and oncolytic virus therapies. The company's GVAX cancer Immunotherapies comprise Prostate Cancer, a phase III product for the treatment of prostate cancer- Pancreatic Cancer, a phase II product for pancreatic cancer- and Leukemia, a phase II product for the treatment of acute and chronic myelogenous leukemia, and myelodysplastic syndrome. Its Oncolytic Virus Therapy includes CG0070, a phase I product for the treatment of recurrent bladder cancer. Cell Genesys has alliance with Novartis AG for the development and commercialization of oncolytic virus therapies- research and development collaboration with Medarex, Inc.- and development and commercialization collaboration of GVAX immunotherapy with Takeda Pharmaceutical Company Limited for prostate cancer. The company was founded in 1988 and is headquartered in South San Francisco, California."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Tue, 22 Jul 2008 12:30:00 Etc/GMT | Final Results From Phase 2 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Published in the American Cancer Society's Journal Cancer (Business Wire) | | Thu, 5 Jun 2008 16:01:00 Etc/GMT | 3 Top PowerRatings Pullbacks Under $10: NLS, RTK, CEGE (TradingMarkets.com) | | Wed, 4 Jun 2008 12:30:00 Etc/GMT | Cell Genesys to Present at the Needham & Company Seventh Annual Biotechnology and Medical Technology Conference (Business Wire) | | Tue, 3 Jun 2008 13:09:19 Etc/GMT | Celgene study shows Vidaza extended lives (at MarketWatch) | | Mon, 2 Jun 2008 12:00:00 Etc/GMT | Cell Genesys Reports Updated Results From Phase 1 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Used in Combination With Ipilimumab (Business Wire) | | Fri, 30 May 2008 15:59:00 Etc/GMT | High PowerRating, Low Price: 5 Stocks for Traders (TradingMarkets.com) | | Fri, 30 May 2008 11:10:16 Etc/GMT | [$$] Feuerstein's Biotech-Stock Mailbag (at RealMoney by TheStreet.com) | | Wed, 28 May 2008 18:17:08 Etc/GMT | A Partnership of Habitual Dealmakers (at Motley Fool) | | Wed, 21 May 2008 16:55:08 Etc/GMT | Cell Genesys bladder cancer drug shows promise in early test (at bizjournals.com) | | Wed, 21 May 2008 12:00:00 Etc/GMT | Cell Genesys Reports Encouraging Interim Data From Phase 1 Clinical Trial of CG0070 in Recurrent Bladder Cancer (Business Wire) | | Mon, 12 May 2008 20:00:00 Etc/GMT | Cell Genesys to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference (Business Wire) | | Mon, 12 May 2008 14:50:45 Etc/GMT | Cell Genesys Issues Stock in Private Placement (at TheStreet.com) | | Mon, 12 May 2008 12:47:06 Etc/GMT | Cell Genesys to sell 7.1 million shares for $30M (AP) | | Mon, 12 May 2008 10:18:27 Etc/GMT | CELL GENESYS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial (EDGAR Online) | | Mon, 12 May 2008 10:00:00 Etc/GMT | Cell Genesys Announces Registered Direct Equity Offering of $30 Million (Business Wire) | | Fri, 9 May 2008 17:00:37 Etc/GMT | Reporters Barred from Ariad, Celgene, Cougar Roundtable? (at CNBC) | | Fri, 9 May 2008 14:19:17 Etc/GMT | Single-Digit Stocks With Swagger (at Forbes.com) | | Wed, 7 May 2008 13:04:51 Etc/GMT | CELL GENESYS INC Financials (EDGAR Online Financials) | | Sun, 4 May 2008 14:33:52 Etc/GMT | New Star Analyst Rankings for CELL GENESYS INC (StarMine) | | Fri, 2 May 2008 22:35:07 Etc/GMT | Cell Genesys shares jump on as 1Q results top Wall Street (AP) | News provided by Yahoo! Finance |
|
